# EDGAR Filing Document

**Accession Number:** 0001606498
**File Stem:** 0001606498-25-000129
**Filing Date:** 2025-11
**Character Count:** 55180
**Document Hash:** c1fa52d32b9aefdcbd34b63f581a33b8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001606498-25-000129.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001606498-25-000129

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251105

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVANOS MEDICAL, INC.
- **CENTRAL INDEX KEY:** 0001606498
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 464987888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36440
- **FILM NUMBER:** 251451698

**BUSINESS ADDRESS:**
- **STREET 1:** 5405 WINDWARD PARKWAY
- **STREET 2:** SUITE 100 SOUTH
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30004
- **BUSINESS PHONE:** 844-428-2667

**MAIL ADDRESS:**
- **STREET 1:** 5405 WINDWARD PARKWAY
- **STREET 2:** SUITE 100 SOUTH
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30004

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avanos Medical, Inc.
- **DATE OF NAME CHANGE:** 20180702

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Halyard Health, Inc.
- **DATE OF NAME CHANGE:** 20140424

?xml version='1.0' encoding='ASCII'? avns-20251105

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

![avanoslogo.jpg](avns-20251105_g1.jpg)

**AVANOS MEDICAL, INC.** 

(Exact name of registrant as specified in its charter)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **001-36440** | **001-36440** | | **46-4987888** |
| (State or other jurisdiction of incorporation) | (State or other jurisdiction of incorporation) | (Commission File Number) | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | **5405 Windward Parkway** | **5405 Windward Parkway** | **5405 Windward Parkway** | **5405 Windward Parkway** | **5405 Windward Parkway** |
| | **Suite 100 South** | **Suite 100 South** | **Suite 100 South** | **Suite 100 South** | **Suite 100 South** |
| | **Alpharetta,** | **Alpharetta,** | **Georgia** | **30004** | **30004** |
| | (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip code) | (Zip code) |

---

**Registrant's telephone number, including area code: (844) 428-2667**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of exchange on which registered |
| **Common Stock - $0.01 Par Value** | **AVNS** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition**

On November 5, 2025, Avanos Medical, Inc. (the "Company") issued a press release announcing its results of operations for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report or Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| <u>[99.1](avns3q2025form8kex991.htm)</u> | <u>[Press release issued by Avanos Medical, Inc. on](avns3q2025form8kex991.htm)[November](avns3q2025form8kex991.htm)[5](avns3q2025form8kex991.htm)[, 2025](avns3q2025form8kex991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | |
|:---|:---|:---|:---|
| | | AVANOS MEDICAL, INC. | AVANOS MEDICAL, INC. |
| Date: | November 5, 2025 | By: | /s/ John J. Hurley |
|  |  |  | John J. Hurley<br>Controller<br>(Principal Accounting Officer) |

---

## Exhibit 99.1

![avanoslogo.jpg](avanoslogo.jpg)<br>

---

| |
|:---|
| Investor Contact: Scott Galovan |
| Avanos Medical, Inc. |
| 470-562-2692 |
| Investor.Relations@Avanos.com |
| Media Contact: Katrine Kubis |
| Avanos Medical, Inc. |
| CorporateCommunications@Avanos.com |

---

**Avanos Medical, Inc. Announces Third Quarter 2025 Results**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Delivered double-digit growth in Specialty Nutrition Systems segment

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Closed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segment

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Raising and narrowing top-line guidance and adjusted EPS guidance for the full year

**ALPHARETTA, Ga., November 5, 2025/PRNewswire/** -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2025 financial results.

"I am pleased with our third quarter results, both operationally and commercially," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Avanos delivered double-digit growth in our life-sustaining Specialty Nutrition Systems segment and made continued progress in our opioid-sparing Pain Management and Recovery segment, all while managing through a challenging tariff environment. In addition, we are excited about the recently completed acquisition of Nexus Medical, which adds complementary technology to our Specialty Nutrition Systems offerings and is expected to deliver immediate value in NICU and PICU care."

**Third Quarter 2025 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total net sales were $177.8 million, a 4.3% increase from the comparable prior year period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss was $1.4 million, compared to net income from continuing operations of $5.9 million a year ago.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income was $10.1 million, compared to $16.7 million a year ago.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Diluted loss per share was $0.03, compared to diluted earnings per share of $0.12 a year ago.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted earnings per share was $0.22, compared to $0.36 a year ago.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA was $20.2 million, compared to $30.6 million a year ago.

**Third Quarter of 2025 Operating Results**

For the three months ended September 30, 2025, net sales totaled $177.8 million, an increase of 4.3% compared to the prior year period, primarily driven by higher volume across both our Specialty Nutrition Systems ("SNS") and Pain Management and Recovery ("PM&R") segments.

Operating profit in the third quarter of 2025 was $0.1 million, compared to operating profit of $12.0 million in the prior year period. On an adjusted basis, operating profit was $15.2 million, compared to $25.3 million last year.

------

**Third Quarter 2025 Segment Results**

*Specialty Nutrition Systems*

The SNS segment delivered above-market results in the third quarter of 2025, achieving net sales of $114.0 million, an increase of $15.8 million compared to the prior year period, with 14.0% volume growth driven by continued strong demand across both our life-sustaining enteral feeding and neonate solutions categories. In enteral feeding, demand for our long-term feeding products remained strong, with above-market growth, while short-term feeding portfolio growth was driven by continued expansion of our US CORTRAK standard of care offerings.

Operating income in the SNS segment for the three months ended September 30, 2025 was $23.0 million, or 20% of SNS net sales, an increase of $4.4 million compared to the prior year period.

*Pain Management & Recovery*

PM&R segment net sales for the third quarter of 2025 was $59.0 million, an increase of $1.2 million compared to the prior year period, with volume growth in Radio Frequency Ablation ("RFA") solution net sales partially offset by reduced volume in our surgical pain and recovery product lines. Net sales of RFA products grew 10.5%, reflecting sustained momentum in RFA generator sales, which resulted in higher procedural volumes across all product lines. Net sales in surgical pain and recovery for the third quarter of 2025 were 7.9% lower than last year, primarily driven by lower volume in our Game Ready product line, while our surgical pain solutions net sales were flat compared to the prior year. Operating income in the PM&R segment for the third quarter of 2025 was $2.0 million compared to $0.8 million last year.

**First Nine Months of 2025 Operating Results** 

For the nine months ended September 30, 2025, net sales were $520.3 million, an increase of 2.4% compared to the prior year period, driven by volume growth across the SNS portfolio and in RFA solutions and partially offset by lower volume in surgical pain and recovery.

Following a $77.0 million impairment charge to goodwill in the second quarter of 2025, operating loss for the nine months ended September 30, 2025 was $64.1 million, compared to an operating income of $22.3 million in the prior year period. On an adjusted basis, operating income for the third quarter was $44.5 million compared to $63.4 million in the prior year period.

**First Nine Months of 2025 Segment Results**

*Specialty Nutrition Systems*

The SNS segment delivered above-market results in the nine months ended September 30, 2025, achieving net sales of $317.8 million, an increase of $27.3 million compared to the prior year period, with 9.1% volume growth driven by continued strong demand across both our enteral feeding and neonate solutions categories.

Operating income in the SNS segment for the nine months ended September 30, 2025 was $62.1 million, or 19.5% of SNS net sales, due to higher volume. This was an increase of $6.3 million compared to the prior year period.

*Pain Management & Recovery*

PM&R segment net sales for the nine months ended September 30, 2025 were $176.2 million, an increase of $2.8 million compared to the prior year period, with volume growth partially offset by the effects of certain revenue streams that we strategically decided not to pursue this year. Net sales of RFA products grew 10.9%, driven by RFA generator sales, which resulted in higher procedure volumes. Net sales in surgical pain and recovery for the nine months ended September 30, 2025 were 8.9% lower than last year.

Operating profit in the PM&R segment for the nine months ended September 30, 2025 was $4.0 million compared to an operating loss of $1.2 million last year.

------

**Non-Cash Goodwill Impairment**

During the second quarter, due to downward pressure on our market capitalization, we assessed goodwill for impairment and recorded an impairment charge of $77.0 million in the PM&R segment.

**Cash Flow and Balance Sheet**

We had $70.5 million of cash on hand as of September 30, 2025 compared to $107.7 million at year-end 2024. Cash flow from operations for the nine months ended September 30, 2025 was $46.5 million, compared to $42.8 million a year ago. Free cash flow for the third quarter of 2025 was $7.0 million compared to $20.0 million in the comparable prior year period. For the nine months ended September 30, 2025, free cash flow was $21.8 million, compared to $29.8 million a year ago. Total debt outstanding, net of unamortized discounts, was $102.8 million at September 30, 2025, compared to $134.7 million at December 31, 2024*.* 

**Sale of HA Product Line**

On July 31, 2025, we announced the divestiture of our HA product line to Channel-Markers Medical, LLC, a privately held company. This transaction aligns with our ongoing transformation, which is focused on advancing our strategic SNS and PM&R segments.

**2025 Outlook**

We are raising and narrowing our 2025 estimated revenue to between $690 million and $700 million and raising and narrowing our adjusted diluted earnings per share guidance, to a new range of between $0.85 and $0.95.

The guidance on adjusted diluted earnings per share range includes the Company's current estimated impact of tariffs. The estimate assumes that management's mitigation plans will be able to moderate the impact of tariffs, including through cost containment measures, pricing actions where appropriate, supply chain adjustments and reliance on existing international agreements that allow for reduced or duty-free importation of products. Tariff rates continue to fluctuate, and if the final tariffs are higher than we anticipate, or if we are unable to successfully mitigate the impact of tariffs, the adverse effect on the Company's business, financial condition, results of operations, cash flows and guidance could be material. The ultimate impact from any tariffs remains uncertain and will depend on various factors, including the level of our imports from China and Mexico, the level of tariff exemptions we are able to achieve, the proportion of our components procured and our finished goods manufactured outside of the United States, and the amount, scope, nature, timing and duration of the tariffs.

**Non-GAAP Financial Measures**

This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted gross and operating income;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted income before taxes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted effective tax rate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted earnings per share;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted selling, general and administrative expenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Free cash flow.

------

These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Certain acquisition and integration charges related to acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expenses associated with restructuring and transformation activities, including the divestiture of the Company's respiratory health business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expenses associated with European Union Medical Device Regulation ("EU MDR") compliance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The amortization of intangible assets associated with business acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Impairments of intangibles or goodwill;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The tax effects of certain adjusting items; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The positive or negative effect of changes in currency exchange rates during the year.

The Company provides these non-GAAP financial measures as supplemental information to its GAAP financial measures. Management and the Company's board of directors use net sales on a constant currency basis, adjusted net income, adjusted diluted earnings per share, adjusted operating income, adjusted EBITDA, and free cash flow to: (a) evaluate the Company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the Company's business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of the Company's ongoing business operations.

Additionally, the compensation committee of the Company's board of directors will use certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the Company's net sales on a constant currency basis and adjusted EBITDA, which will be determined by excluding certain items that are used in calculating these non-GAAP financial measures.

Our competitors may define these non-GAAP financial measures differently, and as a result, our measure of these non-GAAP financial measures may not be directly comparable to those of other companies. Items excluded from these non-GAAP financial measures are significant components in understanding and assessing financial performance. These non-GAAP financial measures are supplemental measures of operating performance that do not represent, and should not be considered in isolation or as an alternative to, or substitute for, the financial statement data presented in the Company's consolidated financial statements as indicators of financial performance. These non-GAAP financial measures have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of the Company's results as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP financial measures as supplemental information.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the attached financial tables.

**Conference Call Webcast**

Avanos Medical, Inc. will host a conference call today at 9 a.m. ET. To instantly join the conference by phone, use the following link to register close to the start time: https://emportal.ink/3OBYJOf. After registering, the system will call you and automatically connect you to the conference call. Alternatively, you may join the call by dialing 1-646-357-8785 or 1-800-836-8184 and you will be connected to the call by an operator. A simultaneous webcast of the call and presentation will be accessible via the Investors section of the Avanos Medical website, <u>https://avanos.investorroom.com</u>. A replay of the call will be available within two hours of the end of the call and will be available for one week. Alternatively, you may dial 1-646-517-4150 or 1-888-660-6345 in the United States and enter passcode 21545#.

**About Avanos Medical, Inc.**

Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to

------

addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio. For more information, visit <u>www.avanos.com</u> and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.

**Forward-Looking Statements**

This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue" and similar expressions. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; shortage in drugs used in our Surgical Pain and Recovery products or other disruptions in our supply chain; the ongoing regional conflicts between Russia and Ukraine and in the Middle East; our ability to successfully execute on or achieve the expected benefits of our transformation initiative or our divestiture, acquisition or merger transactions; inflationary pressures; the expected impact of tariffs and our ability to mitigate tariffs; financial conditions affecting the banking system and the potential threats to the solvency of commercial banks; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment. The information contained herein speaks only as of the date of this release and we undertake no obligation to update forward-looking statements, except as may be required by the securities laws.

Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including our most recent Form 10-Q.

------

**AVANOS MEDICAL, INC.**

**CONDENSED CONSOLIDATED INCOME STATEMENTS**

**(unaudited)**

**(in millions, except per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Net Sales** | $**177.8** | $170.4 | $**520.3** | 508.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of products sold | **91.8** | 77.5 | **252.4** | 224.9 |
| **Gross Profit** | **86.0** | 92.9 | **267.9** | 283.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses | **6.0** | 7.2 | **17.2** | 20.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling and general expenses | **77.6** | 74.3 | **236.8** | 238.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | **—** |  | **77.0** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expense (income), net | **2.3** | (0.6) | **1.0** | 1.7 |
| **Operating Income (Loss)** | **0.1** | 12.0 | **(64.1)** | 22.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | **0.5** | 0.7 | **2.6** | 4.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | **(1.8)** | (3.2) | **(5.9)** | (9.4) |
| **(Loss) Income Before Income Taxes** | **(1.2)** | 9.5 | **(67.4)** | 17.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax provision | **(0.2)** | (3.6) | **(4.2)** | (6.5) |
| **(Loss) Income from Continuing Operations** | **(1.4)** | 5.9 | **(71.6)** | 10.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from discontinued operations, net of tax | **—** | (1.6) | **—** | (5.5) |
| **Net (Loss) Income** | $**(1.4)** | $4.3 | $**(71.6)** | $5.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | $**1.3** | $2.5 | $**3.3** | $5.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax provision | **0.2** | 3.0 | **4.2** | 4.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **9.4** | 11.7 | **29.0** | 34.4 |
| **EBITDA** | $**9.5** | $21.5 | $**(35.1)** | $49.2 |
| **(Loss) Earnings Per Share** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuing operations | $**(0.03)** | $0.13 | $**(1.55)** | $0.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinued operations | **—** | (0.03) | **—** | (0.12) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic (Loss) Earnings Per Share | $**(0.03)** | $0.10 | $**(1.55)** | $0.11 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuing operations | $**(0.03)** | $0.12 | $**(1.55)** | $0.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinued operations | **—** | (0.03) | **—** | (0.12) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted (Loss) Earnings Per Share | $**(0.03)** | $0.09 | $**(1.55)** | $0.11 |
| **Common Shares Outstanding** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | **46.4** | 46.0 | **46.3** | 46.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | **46.4** | 46.6 | **46.3** | 46.5 |

---

------

**AVANOS MEDICAL, INC.**

**Discontinued Operations Summary**

**(unaudited)**

**(in millions, except per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Net Sales** | $**—** | $10.5 | $**—** | $41.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of products sold | **—** | 15.9 | **—** | 47.4 |
| **Gross Profit** | **—** | (5.4) | **—** | (6.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | **—** | (3.2) | **—** | 1.1 |
| **Loss from discontinued operations before income taxes** | **—** | (2.2) | **—** | (7.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit from discontinued operations | **—** | 0.6 | **—** | 2.0 |
| **Loss from discontinued operations, net of tax** | $**—** | $(1.6) | $**—** | $(5.5) |
| **Loss Per Share** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Basic | $**—** | $(0.03) | $**—** | $(0.12) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**—** | $(0.03) | $**—** | $(0.12) |

---

------

**AVANOS MEDICAL, INC.**

**NON-GAAP RECONCILIATIONS**

**(unaudited)**

**(in millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** |
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
| | **Three Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**86.0** | $92.9 | $(5.4) | 87.5 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 0.6 |  | 0.6 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **5.9** | 0.8 |  | 0.8 |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 0.2 |  | 0.2 |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **2.0** | 3.7 |  | 3.7 |
| As adjusted non-GAAP | $**93.9** | $98.9 | $(5.4) | $93.5 |
| Gross profit margin, as reported | **48.4%** | 54.5% | (51.4)% | 48.4% |
| Gross profit margin, as adjusted | **52.8%** | 58.0% | (51.4)% | 51.7% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Gross Profit** | **Gross Profit** | **Gross Profit** | **Gross Profit** |
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| | **Nine Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**267.9** | $283.3 | $(6.4) | $276.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **—** | 0.1 |  | 0.1 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 1.7 |  | 1.7 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 1.4 |  | 1.4 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **10.5** | 3.0 |  | 3.0 |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 0.2 |  | 0.2 |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **7.9** | 10.7 |  | 10.7 |
| As adjusted non-GAAP | $**286.3** | $300.4 | $(6.4) | $294.0 |
| Gross profit margin, as reported | **51.5%** | 55.7% | (15.6)% | 50.4% |
| Gross profit margin, as adjusted | **55.0%** | 59.1% | (15.6)% | 53.5% |

---

------

**AVANOS MEDICAL, INC.**

**NON-GAAP RECONCILIATIONS**

**(unaudited)**

**(in millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Operating Income (Loss)** | **Operating Income (Loss)** | **Operating Income (Loss)** | **Operating Income (Loss)** |
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
| | **Three Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**0.1** | $12.0 | $(2.2) | $9.8 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.4** | 1.6 |  | 1.6 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **10.3** | 2.3 |  | 2.3 |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 1.6 |  | 1.6 |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **4.4** | 6.4 |  | 6.4 |
| As adjusted non-GAAP | $**15.2** | $25.3 | $(2.2) | $23.1 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Operating Income (Loss)** | **Operating Income (Loss)** | **Operating Income (Loss)** | **Operating Income (Loss)** |
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| | **Nine Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**(64.1)** | $22.3 | $(7.5) | $14.8 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.4** | 4.1 |  | 4.1 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 5.2 |  | 5.2 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 2.2 |  | 2.2 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **17.9** | 6.4 |  | 6.4 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment | **77.0** |  |  |  |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 4.4 |  | 4.4 |
| &nbsp;&nbsp;&nbsp;Litigation and legal | **(1.4)** |  |  |  |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **14.7** | 18.8 |  | 18.8 |
| As adjusted non-GAAP | $**44.5** | $63.4 | $(7.5) | $55.9 |

---

------

**AVANOS MEDICAL, INC.**

**NON-GAAP RECONCILIATIONS**

**(unaudited)**

**(in millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Income (Loss) Before Taxes** | **Income (Loss) Before Taxes** | **Income (Loss) Before Taxes** | **Income (Loss) Before Taxes** |
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
| | **Three Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**(1.2)** | $9.5 | $(2.2) | $7.3 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.4** | 1.6 |  | 1.6 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **10.3** | 2.3 |  | 2.3 |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 1.6 |  | 1.6 |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **4.4** | 6.4 |  | 6.4 |
| As adjusted non-GAAP | $**13.9** | $22.8 | $(2.2) | $20.6 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Income (Loss) Before Taxes** | **Income (Loss) Before Taxes** | **Income (Loss) Before Taxes** | **Income (Loss) Before Taxes** |
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| | **Nine Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**(67.4)** | $17.2 | $(7.5) | $9.7 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.4** | 4.1 |  | 4.1 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 5.2 |  | 5.2 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 2.2 |  | 2.2 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **17.9** | 6.4 |  | 6.4 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment | **77.0** |  |  |  |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 4.4 |  | 4.4 |
| &nbsp;&nbsp;&nbsp;Litigation and legal | **(1.4)** |  |  |  |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **14.7** | 18.8 |  | 18.8 |
| As adjusted non-GAAP | $**41.2** | $58.3 | $(7.5) | $50.8 |

---

------

**AVANOS MEDICAL, INC.**

**NON-GAAP RECONCILIATIONS**

**(unaudited)**

**(in millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Tax (Provision) Benefit** | **Tax (Provision) Benefit** | **Tax (Provision) Benefit** | **Tax (Provision) Benefit** |
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
| | **Three Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**(0.2)** | $(3.6) | $0.6 | $(3.0) |
| &nbsp;&nbsp;&nbsp;Tax effects of adjusting items | **(3.6)** | (2.5) |  | (2.5) |
| As adjusted non-GAAP | $**(3.8)** | $(6.1) | $0.6 | $(5.5) |
| Effective tax rate, as reported | **(16.7)%** | 37.9% | 27.3% | 41.1% |
| Effective tax rate, as adjusted | **27.3%** | 26.8% | 27.3% | 26.7% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Tax (Provision) Benefit** | **Tax (Provision) Benefit** | **Tax (Provision) Benefit** | **Tax (Provision) Benefit** |
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| | **Nine Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**(4.2)** | $(6.5) | $2.0 | $(4.5) |
| &nbsp;&nbsp;&nbsp;Tax effects of adjusting items | **(7.0)** | (9.2) |  | (9.2) |
| As adjusted non-GAAP | $**(11.2)** | $(15.7) | $2.0 | $(13.7) |
| Effective tax rate, as reported | **(6.2)%** | 37.8% | 26.7% | 46.4% |
| Effective tax rate, as adjusted | **27.2%** | 26.9% | 26.7% | 27.0% |

---

------

**AVANOS MEDICAL, INC.**

**NON-GAAP RECONCILIATIONS**

**(unaudited)**

**(in millions except per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Net Income (Loss)** | **Net Income (Loss)** | **Net Income (Loss)** | **Net Income (Loss)** |
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
| | **Three Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**(1.4)** | $5.9 | $(1.6) | $4.3 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.4** | 1.6 |  | 1.6 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **10.3** | 2.3 |  | 2.3 |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 1.6 |  | 1.6 |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **4.4** | 6.4 |  | 6.4 |
| &nbsp;&nbsp;&nbsp;Tax effects of adjusting items | **(3.6)** | (2.5) |  | (2.5) |
| As adjusted non-GAAP | $**10.1** | $16.7 | $(1.6) | $15.1 |
| Diluted (loss) earnings per share, as reported | $**(0.03)** | $0.12 | $(0.03) | $0.09 |
| Diluted earnings (loss) per share, as adjusted | $**0.22** | $0.36 | $(0.03) | $0.33 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Net Income (Loss)** | **Net Income (Loss)** | **Net Income (Loss)** | **Net Income (Loss)** |
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| | **Nine Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**(71.6)** | $10.7 | $(5.5) | $5.2 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.4** | 4.1 |  | 4.1 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 5.2 |  | 5.2 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 2.2 |  | 2.2 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **17.9** | 6.4 |  | 6.4 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment | **77.0** |  |  |  |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 4.4 |  | 4.4 |
| &nbsp;&nbsp;&nbsp;Litigation and legal | **(1.4)** |  |  |  |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **14.7** | 18.8 |  | 18.8 |
| &nbsp;&nbsp;&nbsp;Tax effects of adjusting items | **(7.0)** | (9.2) |  | (9.2) |
| As adjusted non-GAAP | $**30.0** | $42.6 | $(5.5) | $37.1 |
| Diluted (loss) earnings per share, as reported | $**(1.55)** | $0.23 | $(0.12) | $0.11 |
| Diluted earnings (loss) per share, as adjusted | $**0.65** | $0.92 | $(0.12) | $0.80 |

---

------

**AVANOS MEDICAL, INC.**

**NON-GAAP RECONCILIATIONS**

**(unaudited)**

**(in millions except per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Selling, General and Administrative Expenses** | **Selling, General and Administrative Expenses** | **Selling, General and Administrative Expenses** | **Selling, General and Administrative Expenses** |
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
| | **Three Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**77.6** | $74.3 | $— | $74.3 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **(0.4)** | (0.7) |  | (0.7) |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | (0.1) |  | (0.1) |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **(2.7)** | (1.5) |  | (1.5) |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | (1.4) |  | (1.4) |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **(2.4)** | (2.7) |  | (2.7) |
| As adjusted non-GAAP | $**72.1** | $67.9 | $— | $67.9 |
| SG&A as a percentage of revenue, as reported | **43.6%** | 43.6% | —% | 41.1% |
| SG&A as a percentage of revenue, as adjusted | **40.6%** | 39.8% | —% | 37.5% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Selling, General and Administrative Expenses** | **Selling, General and Administrative Expenses** | **Selling, General and Administrative Expenses** | **Selling, General and Administrative Expenses** |
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| | **Nine Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| As reported | $**236.8** | $238.8 | $— | $238.8 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **(0.4)** | (1.3) |  | (1.3) |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | (3.4) |  | (3.4) |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | (0.6) |  | (0.6) |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **(5.7)** | (3.4) |  | (3.4) |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | (4.2) |  | (4.2) |
| &nbsp;&nbsp;&nbsp;Intangibles amortization | **(6.8)** | (8.1) |  | (8.1) |
| As adjusted non-GAAP | $**223.9** | $217.8 | $— | $217.8 |
| SG&A as a percentage of revenue, as reported | **45.5%** | 47.0% | —% | 43.5% |
| SG&A as a percentage of revenue, as adjusted | **43.0%** | 42.9% | —% | 39.7% |

---

------

**AVANOS MEDICAL, INC.**

**NON-GAAP RECONCILIATIONS**

**(unaudited)**

**(in millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **EBITDA** | **EBITDA** | **EBITDA** | **EBITDA** |
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
| | **Three Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| **Net (loss) income** | $**(1.4)** | $5.9 | $(1.6) | $4.3 |
| &nbsp;&nbsp;&nbsp;Interest expense, net | **1.3** | 2.5 |  | 2.5 |
| &nbsp;&nbsp;&nbsp;Income tax provision (benefit) | **0.2** | 3.6 | (0.6) | 3.0 |
| &nbsp;&nbsp;&nbsp;Depreciation | **5.0** | 5.3 |  | 5.3 |
| &nbsp;&nbsp;&nbsp;Amortization | **4.4** | 6.4 |  | 6.4 |
| **EBITDA** | **9.5** | 23.7 | (2.2) | 21.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.4** | 1.6 |  | 1.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 0.7 |  | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **10.3** | 2.3 |  | 2.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 1.6 |  | 1.6 |
| **Adjusted EBITDA** | $**20.2** | $30.6 | $(2.2) | $28.4 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **EBITDA** | **EBITDA** | **EBITDA** | **EBITDA** |
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| | **Nine Months Ended September 30, 2025** | **Continuing<br>Operations** | **Discontinued<br>Operations** | **Total** |
| **Net (loss) income** | $**(71.6)** | $10.7 | $(5.5) | $5.2 |
| &nbsp;&nbsp;&nbsp;Interest expense, net | **3.3** | 5.1 |  | 5.1 |
| &nbsp;&nbsp;&nbsp;Income tax provision (benefit) | **4.2** | 6.5 | (2.0) | 4.5 |
| &nbsp;&nbsp;&nbsp;Depreciation | **14.3** | 15.6 |  | 15.6 |
| &nbsp;&nbsp;&nbsp;Amortization | **14.7** | 18.8 |  | 18.8 |
| **EBITDA** | **(35.1)** | 56.7 | (7.5) | 49.2 |
| &nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.4** | 4.1 |  | 4.1 |
| &nbsp;&nbsp;&nbsp;Restructuring and transformation charges | **—** | 5.2 |  | 5.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Post-RH Divestiture transition charges | **—** | 2.2 |  | 2.2 |
| &nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **17.9** | 6.4 |  | 6.4 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment | **77.0** |  |  |  |
| &nbsp;&nbsp;&nbsp;EU MDR Compliance | **—** | 4.4 |  | 4.4 |
| &nbsp;&nbsp;&nbsp;Litigation and legal | **(1.4)** |  |  |  |
| **Adjusted EBITDA** | $**58.8** | $79.0 | $(7.5) | $71.5 |

---

------

**AVANOS MEDICAL, INC.**

**NON-GAAP RECONCILIATIONS**

**(unaudited)**

**(in millions except per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Free Cash Flow** | **Free Cash Flow** | **Free Cash Flow** | **Free Cash Flow** |
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Cash provided by operating activities | $**14.0** | $23.0 | $**46.5** | $42.8 |
| Capital expenditures | **(7.0)** | (3.0) | **(24.7)** | (13.0) |
| Free Cash Flow | $**7.0** | $20.0 | $**21.8** | $29.8 |

---

**2025 OUTLOOK**

---

| | | | |
|:---|:---|:---|:---|
| | **Estimated Range** | **Estimated Range** | **Estimated Range** |
| Diluted earnings per share (GAAP) | $0.43 | to | $0.56 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangibles amortization | 0.25 | to | 0.24 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post RH-Divestiture restructuring charges | 0.12 | to | 0.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 0.05 | to | 0.05 |
| Adjusted diluted earnings per share (non-GAAP) | $0.85 | to | $0.95 |

---

------

**AVANOS MEDICAL, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(unaudited)**

**(in millions)**

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| **ASSETS** | | |
| **Current Assets** | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**70.5** | $107.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | **111.5** | 132.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | **150.6** | 138.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid and other current assets | **18.8** | 14.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Current Assets** | **351.4** | 393.4 |
| **Property, Plant and Equipment, net** | **115.4** | 110.7 |
| **Operating Lease Right-of-Use Assets** | **29.9** | 34.1 |
| **Goodwill** | **394.4** | 455.6 |
| **Other Intangible Assets, net** | **122.0** | 112.3 |
| **Deferred Tax Assets** | **25.3** | 24.9 |
| **Other Assets** | **29.3** | 23.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL ASSETS** | $**1067.7** | $1154.2 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Current Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | $**9.4** | $9.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | **9.5** | 10.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts payable | **54.2** | 54.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | **74.8** | 91.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Current Liabilities** | **147.9** | 165.9 |
| **Long-Term Debt** | **93.4** | 125.3 |
| **Operating Lease Liabilities** | **21.4** | 24.6 |
| **Deferred Tax Liabilities** | **6.3** | 5.5 |
| **Other Long-Term Liabilities** | **20.7** | 4.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES** | **289.7** | 325.7 |
| **Stockholders' Equity** | **778.0** | 828.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY** | $**1067.7** | $1154.2 |

---

------

**AVANOS MEDICAL, INC.**

**CONDENSED CONSOLIDATED CASH FLOW STATEMENTS**

**(unaudited)**

**(in millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Operating Activities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $**(1.4)** | $4.3 | $**(71.6)** | $5.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **9.4** | 11.7 | **29.0** | 34.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | **—** |  | **77.0** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on asset dispositions | **5.4** | 0.1 | **5.7** | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities, net of acquisition | **(2.9)** | 3.7 | **(4.3)** | (10.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes and other | **3.5** | 3.2 | **10.7** | 12.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Cash Provided by Operating Activities** | **14.0** | 23.0 | **46.5** | 42.8 |
| **Investing Activities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | **(7.0)** | (3.0) | **(24.7)** | (13.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the sale of assets | **4.0** |  | **4.0** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from RH Divestiture post-closing settlement | **—** |  | **—** | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition of assets and investments in businesses | **(28.3)** |  | **(28.3)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment in non-affiliates | **(0.2)** | (9.0) | **(4.8)** | (9.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Cash Used in Investing Activities** | **(31.5)** | (12.0) | **(53.8)** | (19.9) |
| **Financing Activities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secured debt repayments | **(2.3)** | (3.2) | **(7.0)** | (6.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revolving credit facility proceeds | **—** |  | **—** | 20.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revolving credit facility repayments | **—** | (10.0) | **(25.0)** | (20.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of treasury stock | **—** | (0.1) | **(3.0)** | (12.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the exercise of stock options | **0.3** | 0.6 | **0.7** | 1.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of contingent consideration liabilities | **—** | (3.3) | **—** | (3.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Cash Used in Financing Activities** | **(2.0)** | (16.0) | **(34.3)** | (21.7) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | **(0.3)** | 1.8 | **4.4** | 0.1 |
| **(Decrease) Increase in Cash and Cash Equivalents** | **(19.8)** | (3.2) | **(37.2)** | 1.3 |
| **Cash and Cash Equivalents - Beginning of Period** | **90.3** | 92.2 | **107.7** | 87.7 |
| **Cash and Cash Equivalents - End of Period** | $**70.5** | $89.0 | $**70.5** | $89.0 |

---

------

**AVANOS MEDICAL, INC.**

**SELECTED BUSINESS SEGMENT DATA**

**(unaudited)**

**(in millions)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**Change** | **2025** | **2024** |<br>**Change** |
| Specialty Nutrition Systems: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enteral feeding | $**82.7** | $72.0 | 14.9% | $**231.7** | $214.7 | 7.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neonate solutions | **31.3** | 26.2 | 19.5% | **86.1** | 75.8 | 13.6% |
| Total Specialty Nutrition Systems | **114.0** | 98.2 | 16.1% | **317.8** | 290.5 | 9.4% |
| Pain Management & Recovery: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Surgical pain and recovery | **24.4** | 26.5 | (7.9)% | **74.1** | 81.3 | (8.9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radiofrequency Ablation | **34.6** | 31.3 | 10.5% | **102.1** | 92.1 | 10.9% |
| Total Pain Management & Recovery | **59.0** | 57.8 | 2.1% | **176.2** | 173.4 | 1.6% |
| Corporate and Other | **4.8** | 14.4 | (66.7)% | **26.3** | 44.3 | (40.6)% |
| **Total Net Sales** | $**177.8** | $170.4 | 4.3% | $**520.3** | $508.2 | 2.4% |
| **Operating Income (Loss)** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specialty Nutrition Systems | $**23.0** | $18.6 | 23.7% | $**62.1** | $55.8 | 11.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pain Management & Recovery | **2.0** | 0.8 | N.M. | **4.0** | (1.2) | N.M. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate and Other<sup>(a)</sup> | **(24.9)** | (7.4) | N.M. | **(130.2)** | (32.3) | N.M. |
| **Total Operating Income (Loss)** | $**0.1** | $12.0 | N.M. | $**(64.1)** | $22.3 | N.M. |
| **Net sales - percentage change (QTD)** |  | **Total** | **Volume** | **Pricing/Mix** | **Currency** | **Other**<sup>(b)</sup> |
| Specialty Nutrition Systems |  | 16.1% | 14.0% | 0.5% | 1.5% | 0.1% |
| Pain Management & Recovery |  | 2.1% | 2.0% | 0.4% | 0.9% | (1.2)% |
| Corporate and Other |  | (66.7)% | (6.1)% | (6.8)% | —% | (53.8)% |
| **Net sales - percentage change (YTD)** |  | **Total** | **Volume** | **Pricing/Mix** | **Currency** | **Other**<sup>(b)</sup> |
| Specialty Nutrition Systems |  | 9.4% | 9.1% | 0.4% | 0.3% | (0.4)% |
| Pain Management & Recovery |  | 1.6% | 2.4% | 0.3% | 0.2% | (1.3)% |
| Corporate and Other |  | (40.6)% | (10.3)% | (15.0)% | (0.1)% | (15.2)% |

---

______________________________

N.M.: Not Meaningful

(a)Corporate and Other operating loss for the nine months ended September 30, 2025 includes $77.0 million of goodwill impairment associated with our PM&R segment.

(b)Other includes the effects of our withdrawal from certain revenue streams that did not meet our return criteria and rounding.

<br>